Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer

被引：13

作者：

Devlies, Wout ^{[1
,2
]}

Eckstein, Markus ^{[3
]}

Cimadamore, Alessia ^{[4
]}

Devos, Gaetan ^{[1
]}

Moris, Lisa ^{[1
,2
]}

van den Broeck, Thomas ^{[1
]}

Montironi, Rodolfo ^{[4
]}

Joniau, Steven ^{[1
]}

Claessens, Frank ^{[2
]}

Gevaert, Thomas ^{[5
]}

机构：

[1] Univ Hosp Leuven, Dept Urol, B-3000 Leuven, Belgium

[2] Katholieke Univ Leuven, Lab Mol Endocrinol, B-3000 Leuven, Belgium

[3] Friedrich Alexander Univ Erlangen Nurnberg, Dept Pathol, D-91054 Erlangen, Germany

[4] Polytech Univ theMarche Reg, United Hosp, Sch Med, Sect Pathol Anat, I-60121 Ancona, Italy

[5] Univ Hosp Leuven, Dept Pathol, B-3000 Leuven, Belgium

来源：

CELLS | 2020年 / 9卷 / 11期

关键词：

prostate cancer; biomarker; targeted therapies; histology; mCRPC; androgen receptor; ANDROGEN-DEPRIVATION THERAPY; CIRCULATING TUMOR-CELLS; POZ PROTEIN SPOP; EMERGING MECHANISMS; RECEPTOR; EXPRESSION; MUTATIONS; GENE; TMPRSS2-ERG; INHIBITORS;

D O I：

10.3390/cells9112494

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

The development of targeted therapies increases treatment options for metastatic castration resistant prostate cancer (mCRPC) patients. There is a need for strong predictive and prognostic signatures to guide physicians in treating mCRPC patients. In this review we unravel the possible actionability in the AR pathway, PI3K AKT signaling, and DNA repair pathways. Additionally, we make recommendations on biomarker trial design, and the clinical use of this new type of data.

引用

页码：1 / 13

页数：13

共 50 条

[31] Study on the Treatment of metastatic castration resistant Prostate Cancer
Rexer, H.
UROLOGE, 2015, 54 (04): : 555 - 557
[32] Olaparib for Metastatic Castration-Resistant Prostate Cancer
Heidegger, Isabel
Pircher, Andreas
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (09): : 890 - 891
[33] METASTATIC PROSTATE CANCER RESISTANT TO CASTRATION IN PERSPECTIVE 2018
Minana Lopez, Bernardino
ARCHIVOS ESPANOLES DE UROLOGIA, 2018, 71 (08): : 625 - 627
[34] Treatment of metastatic, castration-resistant prostate cancer
von Amsberg, G.
Merseburger, A. S.
UROLOGE, 2020, 59 (06): : 673 - 679
[35] THE OBESITY PARADOX IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Martini, Alberto
Cirulli, Giuseppe
Gandaglia, Giorgio
Fossati, Nicola
Necchi, Andrea
Stabile, Armando
Cucchiara, Vito
Mazzone, Elio
Karakiewicz, Pierre I.
Sfakianos, John P.
Galsky, Matthew D.
Oh, William K.
Gallagher, Emily D.
Montorsi, Francesco
Briganti, Alberto
JOURNAL OF UROLOGY, 2021, 206 : E55 - E55
[36] MANAGEMENT OF NON METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Munoz-Velez, Daniel
ARCHIVOS ESPANOLES DE UROLOGIA, 2015, 68 (02): : 125 - 134
[37] Management of Metastatic Castration-Resistant Prostate Cancer
Srinivas, Sandy
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (5.5): : 614 - 616
[38] Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer
Magbanua, Mark Jesus M.
Sosa, Eduardo V.
Scott, Janet H.
Simko, Jeff
Collins, Colin
Pinkel, Dan
Ryan, Charles J.
Park, John W.
BMC CANCER, 2012, 12
[39] Cabazitaxel in metastatic castration-resistant prostate cancer
Yap, Timothy A.
Pezaro, Carmel J.
de Bono, Johann S.
EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (09) : 1129 - 1136
[40] Aurora A in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Rodrigues, Daniel Nava
Mehra, Niven
Figueiredo, Ines
Crespo, Mateus
Riisnaes, Ruth
Miranda, Susana A. A.
Ferreira, Ana
Tunariu, Nina
Perez-Lopez, Raquel
Boysen, Gunther
Sharp, Adam
Bianchini, Diletta
Kolinsky, Michael
Rescigno, Pasquale
Zafeiriou, Zafeiris
Mateo, Joaquin
De Bono, Johann S.
LABORATORY INVESTIGATION, 2016, 96 : 251A - 251A

← 1 2 3 4 5 →